Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF5993 in Advanced COPD (DARWiIN)
NCT04876677Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started May 2021; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04876677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04876677.